Lupin appoints Claus Jepsen as President, Global Specialty

Pradhan Mantri Bhartiya Janaushadhi Pariyojana achieves sales worth Rs. 1,000 croe in Oct. 2024

Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups

Mastek partners Innovaccer to transform value-based care and improve patient experience

This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences

PM Modi inaugurates Rs. 110 crore R Jhunjhunwala Sankara Eye Hospital in Varanasi

Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections

Health Minister Nadda inaugurates Medicine Update BJMFCON 2024

Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020

Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test

Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension

Zydus receives final approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 mg

Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies

Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years

Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years